🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07616102
Starting soon Not applicable

Effect of Bupivacaine Liposome Injection on Muscle Strength After Total Knee Arthroplasty

NCT07616102 · tracked via the Priya Life Science China tracker
Sponsor
General Hospital of Ningxia Medical University
Phase
Not applicable
Started
2026-06-10
Last updated
2026-05-29

Condition(s) studied

TKAMuscle Strength

Investigational drug(s) / intervention(s)

a single-injection adductor canal blockcontinuous femoral nerve block

a single-injection adductor canal block: An ultrasound-guided adductor canal block is performed via the conventional adductor canal approach. Under ultrasound guidance, 20 milliliters of 1.33% bupivacaine liposome is injected into the adductor canal.

continuous femoral nerve block: An ultrasound-guided perineural sheath block of the femoral nerve is performed via the conventional femoral nerve approach. A femoral nerve catheter is then placed and connected to an analgesia pump containing 150 milliliters of 0.20% ropivacaine.

Study summary

This study employs a randomized controlled trial to investigate whether bupivacaine liposome injection for adductor canal block can effectively improve lower limb muscle strength after total knee arthroplasty.

Eligibility

Sex
ALL
Min age
60 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged 60-75 years scheduled for elective TKA; 2. ASA physical status classification II-III; 3. BMI 18-30 kg/m²; 4. Agreement to participate in this study and provision of signed informed consent. Exclusion Criteria: 1. Individuals with communication barriers such as language or hearing impairments; 2. Patients with contraindications to nerve blocks; 3. Severe systemic diseases, such as severe renal disease (estimated glomerular filtration rate below 50 mL/min), cardiac disease (congestive heart failure New York Heart Association Class III to IV), or severe hepatic disease defined as a current or past diagnosis of acute/subacute hepatic necrosis, acute liver failure, chronic liver disease, liver abscess, hepatic coma, or hepatorenal syndrome; 4. History of long-term opioid use (defined as daily or nearly daily opioid use within the past 3 months).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
General hospital of Ningxia medical university Yinchuan Ningxia

More General Hospital of Ningxia Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07616102 on ClinicalTrials.gov ↗ ← All trials in China